
Public Comments and CDC Response Papers
Public Comments
CDC Notification No. | Opening Date | Closing Date | Subject | Status |
01 of 2023 | March 06, 2023 | March 13, 2023 | Proposed amendments in the CDC Regulations relating to Depository Receipt | Closed |
06 of 2022 | August 30, 2022 | September 06, 2022 | Proposed amendments in the CDC Regulations relating to Various Matters | Closed |
05 of 2022 | August 23, 2022 | August 30, 2022 | Proposed amendments in the Fees & Deposits of Schedule | Closed |
04 of 2022 | June 01, 2022 | June 08, 2022 | Proposed amendments in the CDC Regulations relating to Introduction of the Centralized Gateway Portal | Closed |
03 of 2022 | April 25, 2022 | May 02, 2022 | Proposed amendments in the CDC Regulations relating to Introduction of Savings Certificates and related matters | Closed |
02 of 2022 | March 07, 2022 | March 14, 2022 | Amendments in the Schedule of Fees & Deposits | Closed |
01 of 2022 | February 21, 2022 | February 28, 2022 | Proposed amendments in the CDC Regulations relating to Various Matters | Closed |
07 of 2021 | September 10, 2021 | September 17, 2021 | Proposed Amendments in the Fees & Deposits Schedule | Closed |
06 of 2021 | July 30, 2021 | August 06, 2021 | Proposed Amendments in the Fees & Deposits Schedules | Closed |
05 of 2021 | June 17, 2021 | June 24, 2021 | Proposed amendments in the CDC Regulations relating to Shared KYC Information | Closed |
04 of 2021 | May 04, 2021 | May 11, 2021 | Amendments in the Schedule of Fees for Investor Account Services | Closed |
03 of 2021 | April 22, 2021 | April 29, 2021 | Proposed amendments in the CDC Regulations relating to Settlement of Listed Debt Securities by the Market Maker | Closed |
02 of 2021 | March 26, 2021 | April 02, 2021 | Amendments in the Schedule of Fees & Deposits | Closed |
01 of 2021 | March 11, 2021 | March 18, 2021 | Proposed amendments in the CDC Regulations relating to Various Matter | Closed |
- CDC invites the interested parties to provide their comments and views, with specific reference to the subject matter of the proposed amendments to CDC Regulations notified via notices, through any of the following modes.
|
|
|
The Chief Compliance Officer, |
- At the time of submission of comments, respondent is advised to provide the information, as per Table-A below, so that CDC may contact him/her for clarification or deliberation on the comments, if needed. Anonymous responses may be disregarded by CDC.
Table A
To Be Filed By The Respondent | |
Name of respondent |
|
Account No. |
|
Name of company (if applicable) |
|
Designation (if applicable) |
|
Contact Number |
|
Email Address |
- The respondent may request confidential treatment for his/ her identity and all or any part of comments due to their proprietary, confidential or commercial nature, by clearly marking the information in Table-B below:
Table B
Disclosure of Identity and Comments |
Please check the box(es) if you wish to be remain confidential:
|
If respondent wishes to keep any part(s) of comments confidential, then he/she is required to clearly specify such part(s) of comments.
- To ensure quality and promote transparency, CDC will publish the relevant comments of respondents and its management’s response thereon in the form of a Response Paper on its website, within a reasonable timeframe, after close of public consultation session, unless the respondent has made a confidentiality request.
- Any policy or rule amendment may be subject to regulatory concurrence. For this purpose, respondents should note that notwithstanding any confidentiality request, CDC will share all their response(s) with the Securities and Exchange Commission of Pakistan (Apex Regulator).
- By submitting comments, respondents are deemed to have consented to the collection, use and disclosure of data that is provided to CDC, unless respondents wish to have their identity or comments remain confidential.
Date |